Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.

doi:10.1016/j.cllc.2023.12.009

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.

Clinical lung cancer - 1 May 2024

Barsouk Adam, Friedes Cole, Iocolano Michelle, Doucette Abigail, Cohen Roger B, Robinson Kyle W, D'Avella Christopher A, Marmarelis Melina E, Kosteva John A, Singh Aditi P, Ciunci Christine A, Levin William P, Cengel Keith A, Bradley Jeffrey D, Feigenberg Steven J, Sun Lova, Aggarwal Charu, Langer Corey J, Yegya-Raman Nikhil

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitor (ICI) consolidation following concurrent chemoradiotherapy (CRT) substantially improved progression free survival (PFS) and overall survival (OS) in the PACIFIC trial becoming the standard of care in locally-advanced, unresectable NSCLC. KRAS mutation may influence response to ICI. METHODS: In this single-institution, retrospective analysis, we compared treatment outcomes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to Carcinoma, Non-Small-Cell Lung

Share to Chemoradiotherapy

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 38195320
DOI: 10.1016/j.cllc.2023.12.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.PMID 38195320Read ↗

Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.Semantic proximity Read ↗

Equalizing prognostic disparities in stage III KRAS-mutant NSCLC: addition of durvalumab to combined chemoradiotherapy improves survivalSemantic proximity Read ↗

Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.Semantic proximity Read ↗

Survival outcomes in EGFR-mutant versus wild-type locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy alone in the pre-PACIFIC/LAURA trial era: A systematic review and meta-analysis using reconstructed individual patient data.Semantic proximity Read ↗

Concurrent Chemoradiation in Locally Advanced Lung Cancer with Cisplatin–Etoposide or Carboplatin–Paclitaxel: An Institutional AnalysisSemantic proximity Read ↗

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.Semantic proximity Read ↗

Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations.Semantic proximity Read ↗

Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort.Semantic proximity Read ↗

Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy.Semantic proximity Read ↗

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With ImmunotherapySemantic proximity Read ↗

Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.